Show simple item record

Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations

dc.contributor.authorAyres, James W.en_US
dc.contributor.authorStoll, Roger G.en_US
dc.contributor.authorSakmar, Ermelindaen_US
dc.contributor.authorHallmark, Margarette R.en_US
dc.contributor.authorWagner, John G.en_US
dc.contributor.authorWeidler, Donald J.en_US
dc.date.accessioned2006-09-11T15:38:40Z
dc.date.available2006-09-11T15:38:40Z
dc.date.issued1979-04en_US
dc.identifier.citationWagner, J. G.; Stoll, R. G.; Weidler, D. J.; Ayres, J. W.; Hallmark, M. R.; Sakmar, E.; (1979). "Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations." Journal of Pharmacokinetics and Biopharmaceutics 7(2): 147-158. <http://hdl.handle.net/2027.42/45076>en_US
dc.identifier.issn0090-466Xen_US
dc.identifier.issn1573-8744en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45076
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=20218011&dopt=citationen_US
dc.description.abstractA blinded, four-treatment crossover study in 16 normal adult male volunteers compared plasma concentrations and urinary excretion of digoxin, measured by radioimmunoassay, after oral administration of soft gelatin capsule formulations of digoxin. Four 0.4-mg formulations with different in vitro “burst times” and dissolution rates were administered, with 2- week intervals between treatments. The two capsules with lowest in vitro burst times (2.9 and 16 min) gave comparable in vivo results. The other two capsules, with in vitro burst times of 62 and 229 min, produced significant delays in digoxin absorption . In vitro-in vivo correlations were obtained by comparing the logarithm of the in vitro burst time with time to peak plasma level and the time to the first measurable plasma level (≥ 0.05 ng/ml). Also, the mean time to peak plasma level correlated with the logarithm of the time required to release either 50% or 85% of the digoxin in vitro. No significant changes were found in the amount of digoxin absorbed from each capsule as determined by urinary excretion or AUC 0-∞ .en_US
dc.format.extent530956 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherCorrelationsen_US
dc.subject.otherDigoxin Bioavailabilityen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherPharmacyen_US
dc.subject.otherVeterinary Medicineen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherIn Vitro-in Vivoen_US
dc.subject.otherDigoxin Radioimmunoassayen_US
dc.subject.otherPlasma Concentrations and Urinary Excretion of Digoxinen_US
dc.subject.otherGelatin Capsule Formulationsen_US
dc.titleComparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulationsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michiganen_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michigan; School of Pharmacy, Oregon State University, 97331, Corvallis, Oregonen_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michiganen_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Biopharmaceutical Sciences, Arnar-Stone Laboratories, Inc., 60085, McGraw Park, Illinoisen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid20218011en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45076/1/10928_2005_Article_BF01059735.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF01059735en_US
dc.identifier.sourceJournal of Pharmacokinetics and Biopharmaceuticsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.